Holen Sie sich die Stockscreener-App
103.29
1.44%
-1.51
Handel nachbörslich:
103.21
-0.08
-0.08%
Schlusskurs vom Vortag:
$104.80
Offen:
$105.13
24-Stunden-Volumen:
5.27M
Relative Volume:
0.65
Marktkapitalisierung:
$152.66B
Einnahmen:
$17.55B
Nettoeinkommen (Verlust:
$2.03B
KGV:
75.39
EPS:
1.37
Netto-Cashflow:
$2.72B
1W Leistung:
+0.10%
1M Leistung:
+13.96%
6M Leistung:
+17.04%
1J Leistung:
+42.04%
1-Tages-Spanne:
$103.22
$105.74
1-Wochen-Bereich:
$103.10
$105.74
52-Wochen-Spanne:
$71.88
$107.17
Boston Scientific Corp Stock (BSX) Company Profile
Firmenname
Boston Scientific Corp
Sektor
Branche
Telefon
508-683-4000
Adresse
300 BOSTON SCIENTIFIC WAY, MARLBOROUGH, MA
Vergleichen Sie BSX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BSX
Boston Scientific Corp
|
103.29 | 152.66B | 17.55B | 2.03B | 2.72B | 1.37 |
|
ABT
Abbott Laboratories
|
134.00 | 227.71B | 42.34B | 13.50B | 6.66B | 7.71 |
|
SYK
Stryker Corp
|
382.46 | 142.93B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
83.62 | 107.17B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
74.63 | 44.04B | 5.54B | 4.18B | 623.10M | 7.00 |
Boston Scientific Corp Stock (BSX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-16 | Hochstufung | Needham | Hold → Buy |
| 2025-01-10 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2024-10-18 | Herabstufung | Needham | Buy → Hold |
| 2024-05-30 | Eingeleitet | Goldman | Buy |
| 2024-02-01 | Hochstufung | Mizuho | Neutral → Buy |
| 2023-07-19 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-06-30 | Eingeleitet | CL King | Buy |
| 2023-05-30 | Fortgesetzt | Morgan Stanley | Overweight |
| 2023-03-29 | Eingeleitet | UBS | Buy |
| 2022-12-22 | Eingeleitet | Mizuho | Neutral |
| 2022-12-20 | Fortgesetzt | Citigroup | Buy |
| 2022-10-18 | Eingeleitet | Barclays | Overweight |
| 2022-10-12 | Eingeleitet | Jefferies | Buy |
| 2022-07-06 | Eingeleitet | Wolfe Research | Outperform |
| 2022-05-27 | Hochstufung | Needham | Hold → Buy |
| 2022-04-13 | Fortgesetzt | Truist | Buy |
| 2022-03-02 | Fortgesetzt | BofA Securities | Buy |
| 2021-12-10 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-05-26 | Herabstufung | Needham | Buy → Hold |
| 2021-05-25 | Eingeleitet | Barclays | Overweight |
| 2021-04-15 | Eingeleitet | Atlantic Equities | Overweight |
| 2020-09-17 | Eingeleitet | Truist | Buy |
| 2020-09-11 | Eingeleitet | Wolfe Research | Peer Perform |
| 2020-04-22 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2020-04-01 | Hochstufung | Goldman | Neutral → Buy |
| 2020-03-05 | Eingeleitet | Citigroup | Buy |
| 2020-02-13 | Eingeleitet | Goldman | Neutral |
| 2020-02-06 | Fortgesetzt | BTIG Research | Buy |
| 2019-12-30 | Bestätigt | Cowen | Outperform |
| 2019-12-19 | Herabstufung | Needham | Strong Buy → Buy |
| 2019-09-05 | Fortgesetzt | JP Morgan | Overweight |
| 2019-09-03 | Fortgesetzt | Barclays | Overweight |
| 2019-05-13 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2018-11-28 | Eingeleitet | UBS | Buy |
| 2018-10-16 | Eingeleitet | Barclays | Overweight |
| 2018-10-02 | Bestätigt | Morgan Stanley | Overweight |
| 2018-09-07 | Bestätigt | Needham | Strong Buy |
| 2018-09-04 | Hochstufung | Jefferies | Hold → Buy |
| 2018-07-06 | Bestätigt | Needham | Strong Buy |
| 2018-06-27 | Eingeleitet | Bernstein | Outperform |
| 2018-04-26 | Bestätigt | Needham | Strong Buy |
Alle ansehen
Boston Scientific Corp Aktie (BSX) Neueste Nachrichten
Erste Group initiates Boston Scientific with Buy, sees growth - Investing.com
Boston Scientific (BSX) Coverage Reinstated with Buy Rating by Analyst | BSX Stock News - GuruFocus
Boston Scientific completes SoniVie acquisition - MassDevice
Insider Sell: John Sorenson Sells Shares of Boston Scientific Corp (BSX) - GuruFocus
Boston Scientific Corporation (BSX) Announces Results of 2025 Annual Meeting of Stockholders - GuruFocus
Are Wall Street Analysts Predicting Boston Scientific Stock Will Climb or Sink? - Nasdaq
Are Wall Street Analysts Predicting Boston Scientific Stock Will Climb Or Sink? - Barchart.com
Boston Scientific Chief Financial Officer (CFO) Dan Brennan to retire; Jon Monson, senior vice president, Investor Relations to succeed Brennan - ADVFN
Boston Scientific, FDA Sued Over 'Unsafe' Spinal Implant - Law360
A Changing of the Guard at Boston Scientific, Wright Medical Group and Vision-Sciences - Medical Product Outsourcing
Can Boston Scientific Corporation (NYSE:BSX) Performance Keep Up Given Its Mixed Bag Of Fundamentals? - Yahoo Finance
Beyond the Balance Sheet: What SWOT Reveals About Boston Scienti - GuruFocus
$100 Invested In Boston Scientific 15 Years Ago Would Be Worth This Much Today - Benzinga
June 13th Options Now Available For Boston Scientific (BSX) - Nasdaq
BOSTON SCIENTIFIC CORP SEC 10-Q Report - TradingView
Here are the highest-paid Mass. life sciences CEOs - The Business Journals
Edwards Lifesciences Corporation (EW): Jim Cramer Says It’s a Hold — But Is Boston Scientific Now His Favorite? - Insider Monkey
Zacks Investment Ideas Feature Highlights: Boston Scientific, Meta Platforms And Microsoft - Barchart.com
Boston Scientific Announces Results for Second Quarter 2024 - Quantisnow
Indexes Take A Well-Deserved Pause; SAP, Boston Scientific, Credicorp In Focus - Investor's Business Daily
EMEA Growth & Product Launches to Support Boston Scientific Stock - MSN
The Zacks Analyst Blog Highlights Abbott Laboratories, Boston Scientific And Medtronic - Barchart.com
The Zacks Analyst Blog Highlights Walmart, Toyota Motor, Boston Scientific and Autoscope - Yahoo Finance
Boston Scientific has positive ICD, Watchman FLX, AI data - MassDevice
Top Stock Reports for Walmart, Toyota Motor & Boston Scientific - MSN
Here is Why Growth Investors Should Buy Boston Scientific (BSX) Now - Yahoo Finance
Boston Scientific CFO Dan Brennan to retire after nearly 30 years with the company - MedTech Dive
Boston Scientific reports outcomes from Farapulse and Farapoint trial - Yahoo Finance
Boston Scientific (BSX) Price Target Raised by Barclays Followin - GuruFocus
Here's Why Boston Scientific (BSX) is a Strong Momentum Stock - Yahoo Finance
Boston Sci expects $200M tariff hit, still raises guidance - BioWorld MedTech
Boston Scientific has positive Farapulse, Farapoint data - MassDevice
Boston Scientific (BSX) Reports Positive Results for FARAPULSE S - GuruFocus
Boston Scientific (BSX) Reports Positive Results for FARAPULSE System in Atrial Fibrillation Study | BSX Stock News - GuruFocus
Second phase of ADVANTAGE AF study of FARAPULSE™ Pulsed Field Ablation System meets primary safety and efficacy endpoints – Company AnnouncementFT.com - Financial Times
Boston Scientific (NYSE:BSX) Announces CFO Retirement And Strong Earnings Growth - Yahoo Finance
Boston Scientific Analysts Boost Their Forecasts Following Upbeat Results - Benzinga
Global Neuroprosthetics Market Expanding Rapidly at a CAGR of ~13% by 2032 Amid Surge in Demand for Advanced Neurological Treatments | DelveInsight - GlobeNewswire Inc.
Boston Scientific's Heart Device Success Lifts 2025 Profit Forecast - Finimize
Boston Scientific (BSX) Price Target Raised to $117 by Truist An - GuruFocus
RBC Capital lifts Boston Scientific stock target to $120 - Investing.com
Why Boston Scientific (BSX) is a Top Growth Stock for the Long-Term - Nasdaq
Boston Scientific (BSX) Price Target Raised by Baird Amid Strong Q1 Performance | BSX Stock News - GuruFocus
Boston Scientific (BSX) Target Price Boosted by RBC Capital Afte - GuruFocus
Canaccord maintains Buy rating on Boston Scientific stock - Investing.com
Raymond James Adjusts Boston Scientific (BSX) Price Target, Reaffirms Strong Buy | BSX Stock News - GuruFocus
Boston Scientific Corporation (NYSE:BSX) Q1 2025 Earnings Call Transcript - Insider Monkey
Canaccord maintains Buy rating on Boston Scientific stock By Investing.com - Investing.com UK
Boston Scientific Stock (BSX): Solid Q1 Earnings Growth - Value The Markets
Petri Dish: Boston Scientific CFO retires; Biotech undergoes 1-for-20 reverse stock split - The Business Journals
Boston Scientific Corp (BSX) Q1 2025 Earnings Call Highlights: Strong Growth and Upgraded ... - Yahoo Finance
Finanzdaten der Boston Scientific Corp-Aktie (BSX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.42%
0.55%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):